Translational paradigms in pharmacology and drug discovery

被引:20
作者
Mullane, Kevin [1 ]
Winquist, Raymond J. [2 ]
Williams, Michael [3 ]
机构
[1] Profectus Pharma Consulting Inc, San Jose, CA 95125 USA
[2] Vertex Pharmaceut Inc, Dept Pharmacol, Cambridge, MA USA
[3] Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
Pharmacology; Translational science; Drug discovery; Bias; Biomarkers; PLURIPOTENT STEM-CELLS; GENOME-WIDE ASSOCIATION; ANIMAL-MODELS; HUMAN-DISEASE; BIOMEDICAL-RESEARCH; CIRCADIAN-RHYTHMS; TARGET IDENTIFICATION; NUCLEAR ARCHITECTURE; THERAPEUTIC TARGETS; HUNTINGTONS-DISEASE;
D O I
10.1016/j.bcp.2013.10.019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The translational sciences represent the core element in enabling and utilizing the output from the biomedical sciences and to improving drug discovery metrics by reducing the attrition rate as compounds move from preclinical research to clinical proof of concept. Key to understanding the basis of disease causality and to developing therapeutics is an ability to accurately diagnose the disease and to identify and develop safe and effective therapeutics for its treatment. The former requires validated biomarkers and the latter, qualified targets. Progress has been hampered by semantic issues, specifically those that define the end product, and by scientific issues that include data reliability, an overt reductionistic cultural focus and a lack of hierarchically integrated data gathering and systematic analysis. A necessary framework for these activities is represented by the discipline of pharmacology, efforts and training in which require recognition and revitalization. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:189 / 210
页数:22
相关论文
共 295 条
[1]   Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].
Abifadel, M ;
Varret, M ;
Rabès, JP ;
Allard, D ;
Ouguerram, K ;
Devillers, M ;
Cruaud, C ;
Benjannet, S ;
Wickham, L ;
Erlich, D ;
Derré, A ;
Villéger, L ;
Farnier, M ;
Beucler, I ;
Bruckert, E ;
Chambaz, J ;
Chanu, B ;
Lecerf, JM ;
Luc, G ;
Moulin, P ;
Weissenbach, J ;
Prat, A ;
Krempf, M ;
Junien, C ;
Seidah, NG ;
Boileau, C .
NATURE GENETICS, 2003, 34 (02) :154-156
[2]  
Accenture and CMR International, 2005, RETH INN PHARM R D
[3]   Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets [J].
Aggarwal, Bharat B. ;
Sung, Bokyung .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (02) :85-94
[4]   Biomarkers in pharmacology and drug discovery [J].
Anderson, D. C. ;
Kodukula, Krishna .
BIOCHEMICAL PHARMACOLOGY, 2014, 87 (01) :172-188
[5]   How to stop plagiarism [J].
不详 .
NATURE, 2012, 481 (7379) :21-23
[6]  
[Anonymous], 2004, INN STAGN CHALL OPP
[7]  
[Anonymous], 2012, The R&D cost of a new medicine
[8]  
[Anonymous], KNOWLEDGE EC
[9]  
[Anonymous], 2011, RETRACTION WATCH
[10]  
[Anonymous], HDB BIOL STAT